CD68 and non-small cell lung carcinoma: Other researchers too have found such enhanced glycolysis in TAMs and have recognized more subtypes of TAMs in cancer like CD68+ TAM in non-small cell lung cancer (NSCLC) (74), CD169+ macrophages in PADC (75, 76), CD163+ macrophages in epithelial ovarian cancer (77), and PD-1+ macrophages in primary mouse and human cancer (78).